BamSEC and AlphaSense Join Forces
Learn More

TuHURA Biosciences Inc.

NASDAQ: HURA    
Share price (1/8/25): $4.17    
Market cap (1/8/25): $176 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.4
from 8-K 8 pages Exhibit B Form of Lock-Up Agreement
12/34/56
EX-10.3
from 8-K 12 pages Form of Parent Stockholder Support Agreement TuHURA Biosciences, Inc
12/34/56
EX-10.2
from 8-K 14 pages Form of Company Stockholder Support Agreement Kineta, Inc
12/34/56
EX-10.1
from 8-K 24 pages Clinical Trial Funding Agreement
12/34/56
EX-10.1
from 8-K 6 pages TuHURA Biosciences, Inc. 2024 Equity Incentive Plan Stock Option Agreement
12/34/56
EX-10.4
from 8-K 16 pages Omnibus Equity Incentive Plan Tuhura Biosciences, Inc. 2024 Equity Incentive Plan
12/34/56
EX-10.2
from 8-K 10 pages Indemnity Agreement
12/34/56
EX-10.32
from 10-K 6 pages Amendment to Executive Employment Agreement
12/34/56
EX-10.41
from S-4/A 9 pages Exclusivity and Right of First Offer Agreement
12/34/56
EX-10.40
from S-4 25 pages Asset Purchase Agreement by and Between Tuhura Biopharma Inc. and Morphogenesis, Inc. Dated as of January 26, 2023
12/34/56
EX-10.39
from S-4 30 pages [***] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because the Information (I) Is Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed Restated and Amended Exclusive License Agreement
12/34/56
EX-10.38
from S-4 35 pages [***] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because the Information (I) Is Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed Exclusive License Agreement
12/34/56
EX-10.37
from S-4 46 pages [***] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because the Information (I) Is Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed Exclusive License Agreement
12/34/56
EX-10.36
from S-4 12 pages Employment Agreement
12/34/56
EX-10.35
from S-4 13 pages Second Amended and Restated Employment Agreement
12/34/56
EX-10.34
from S-4 13 pages Second Amended and Restated Employment Agreement
12/34/56
EX-10.33
from S-4 5 pages Morphogenesis, Inc. Stock Option Agreement
12/34/56
EX-10.32
from S-4 15 pages Amended & Restated Equity Incentive Plan Morphogenesis, Inc. Adopted on January 13, 2019
12/34/56
EX-10.4
from 8-K 18 pages Form of Contingent Value Rights Agreement Recitals
12/34/56
EX-10.4
from 425 18 pages Form of Contingent Value Rights Agreement Recitals
12/34/56